SUPPLEMENT

Q3 2026 — Investor materials

Q3 2026PDF · 6 pages360 KB
September 16, 2026
2026 Q3 Economic Factors and J&J Announcements
Below is a high-level summary of current macro-economic factors, notable announcements made this quarter, as well
as public commentary made by management during the quarter and recent earnings calls. Any additional information
included herein is provided as phasing considerations and should not be construed as guidance.
As a reminder, please note the following:
• 	On July 29, 2026, J&J published a Form 8-K with updated FY 2026 guidance, as a result of the following
transactions:
o 	As communicated on July 29, 2026, J&J completed the acquisition of Firefly Bio and disclosed that
the transaction will be accounted for as an asset acquisition, resulting in an approximately $1 billion
in-process R&D charge in 3Q26 and an expected dilution to adjusted operational EPS and adjusted
EPS of approximately $0.46 in 2026 and $0.08 in 2027
o 	As communicated on July 29, 2026, J&J announced its collaboration and option agreement with Sail
Biomedicines, including an upfront commitment of approximately $785 million (including a $465
million equity investment), with the transaction expected to dilute adjusted operational EPS and
adjusted EPS by approximately $0.18 in 2026 and $1.28 in 2027 (contingent on specified milestones
and exercise of the acquisition option)
o 	The FY 2026 impacts disclosed above primarily relate to transactions completed and/or entered
into during Q3 2026.
• 	In Q4 2025 the company provided full-year 2026 projected average shares outstanding (diluted) guidance of
~2,440 million shares
• 	As reinforced in our Q4 2025 call, we continue to expect earnings to be commensurate with sales growth,
adjusted for the impact of the transactions discussed above.
Macro-economic factors:
• 	Interest Rates: The Federal Funds Rate continues to impact the financing cost of our commercial paper as
well as interest income on our cash position.
• 	Tariffs: In Q2 2026 we noted additional margin improvement beyond initial expectations, partially supported
by the anticipated reduction and recoupment of certain tariff-related costs based on the latest rulings. We
continue to monitor tariffs and their potential impact to our business.
• 	Global Affairs: As described in our Form 10-K risk factors, we have experienced, and expect to continue to
experience, impacts to the Company's business resulting from the Russia-Ukraine war, conflict in the Middle
East as well as increasing tensions between the U.S. and China.
• 	Foreign Exchange: We do not offer guidance or predictions on currency movements, but as highlighted by Joe
during the Q2 2026 earnings call, we utilized the Euro Spot Rate relative to the U.S. dollar of 1.15. The Euro
Spot Rate averaged 1.14 in July, 1.16 in August, compared to a current spot rate of approximately 1.16 over the
past two weeks. As a reminder, our results are based on a basket of currencies, of which, not all align to the
Euro.
Conference and event participation
J&J conference and event participation (transcripts and webcasts) throughout the quarter can be found here.
• 	2026 Wells Fargo Healthcare Conference: Tim Schmid – Executive Vice President & Worldwide Chairman,
MedTech fireside chat with Larry Biegelsen - Wells Fargo Securities, LLC, Analyst
• 	Morgan Stanley 24th Annual Global Healthcare Conference: Joaquin Duato - Chairman and Chief Executive
Officer and John Reed - Executive Vice President, Innovative Medicine, Research and Development, fireside
chat with Terence Flynn – Morgan Stanley, Analyst
• 	2026 Deutsche Bank Healthcare Summit: Joseph Wolk – Chief Financial Officer, Executive Vice President,
fireside chat

-- 1 of 6 --

• 	Johnson and Johnson OTTAVA Investor Call: Tim Schmid - Executive Vice President, Worldwide Chairman of
MedTech, Hani Abouhalka - Company Group Chairman, Surgery of MedTech, Rocco De Bernardis - Global
President Robotic & Digital Surgery – OTTAVA, Neda Cvijetic - Senior Vice President, Global Head R&D,
Robotics and Digital, and Dr. Dominic Papandria - Senior Director of Medical Affairs of OTTAVA Investor Call
and Q&A
• 	Society of Robotic Surgery (SRS) Annual Meeting: Tim Schmid - Executive Vice President, Worldwide
Chairman of MedTech and Hani Abouhalka - Company Group Chairman, Surgery of MedTech fireside chat

-- 2 of 6 --

Announcements
Press releases issued during the quarter can be found on the J&J Media Center, Innovative Medicine Newsroom,
and MedTech News & Events page.
• 	M&A: Johnson & Johnson Completes Acquisition of Firefly Bio, Inc.
• 	Talc: please visit factsabouttalc.com for the latest company statements
o 	J&J announced a proposed resolution of the remaining ovarian talc litigation, including a $5.5 billion
commitment, with the first payment of up to $3 billion in 2027. Any necessary reserve adjustments
will impact GAAP results.
• 	Enterprise: Collaboration with TIME to Introduce New Healthcare Champion of the Year Award; Tom
Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine
• 	Innovative Medicine:
o 	In Vivo CAR-T: Collaboration with Sail Biomedicines to Advance in Vivo CAR-T Programs
o 	CAPLYTA: New neuropsychiatry data at Psych Congress 2026
o 	IMAAVY: FDA wAIHA approval
o 	RYBREVANT FASPRO: U.S. FDA Priority Review
o 	RYBREVANT: Phase 3 PAPILLON study
o 	TECVAYLI + TALVEY: Phase 3 MonumenTAL-6 study
• 	MedTech:
o 	OTTAVA: FDA Market Authorization in the U.S.
o 	Vision: ACUVUE OASYS MAX Reusable CE Marking

-- 3 of 6 --

J&J earnings calls:
• 	Q2 2026 earnings call: For your convenience, the final Q2 2026 earnings transcript and presentation are
attached. Full Q2 2026 earnings call operational commentary and key drivers can be listened to here and the
Q2 2026 10-Q can be found here.
• 	Q3 2025 earnings call: For ease of reference, below are related sales and EPS absolute figures and growth
rates for Q3 2025. Full Q3 2025 operational commentary, key drivers, and one-timers can be listened to here
and the Q3 2025 10-Q can be found here. For your convenience, the final Q3 2025 earnings transcript and
presentation are attached.
Q3 2025:
o 	Enterprise: $24.0B, 5.4% operational sales growth and 4.4% adjusted operational sales growth
 	Enterprise sales highlights can be found on page 6 of the final Q3 2025 earnings transcript attached
 	P&L highlights can be found on page 7 of the final Q3 2025 earnings transcript attached
o 	Innovative Medicine: $15.6B, 5.3% operational sales growth
 	Innovative Medicine sales highlights can be found on page 6 of the final Q3 2025 earnings transcript
attached
o 	MedTech: $8.4B, 5.6% operational sales growth
 	MedTech sales highlights can be found on page 7 of the final Q3 2025 earnings transcript attached
• 	For your convenience, as we progress through 2026, we have attached QTD and FY segment P&Ls for 2025.
Note to investors concerning forward-looking statements:
This document contains forward-looking statements. The reader is cautioned not to rely on these forward-looking
statements, which are based on current expectations of future events. If underlying assumptions prove inaccurate or
known or unknown risks or uncertainties materialize, actual results could vary materially from our current expectations
and projections. A further list and description of these risks, uncertainties and other factors can be found in Johnson
& Johnson’s SEC filings, including our 2025 Form 10-K, which are available at investor.jnj.com and on the SEC’s website.
Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson
does not undertake to update any forward-looking statement as a result of new information or future events or
developments.
Non-GAAP financial measures:
This document refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be
considered replacements for, and should be read together with, the most comparable GAAP financial measures. A
reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be
found in the Investor Relations section of Johnson & Johnson’s website. Johnson & Johnson is not providing
reconciliations for forward-looking non-GAAP financial measures because Johnson & Johnson does not provide GAAP
financial measures on a forward-looking basis, as the company is unable to predict with reasonable certainty the
ultimate outcome of adjusted items, such as legal proceedings, unusual gains and losses, acquisition-related expenses,
and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on
various factors, and could be material to Johnson & Johnson’s results computed in accordance with GAAP.

-- 4 of 6 --

1 	Other segment items for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development
2 	Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the 	company's website
2025
(Unaudited; Dollar in millions)
Earnings before provision for taxes on income by segment
1
Innovative Medicine
Amount 	% to Sales 	Amount 	% to Sales 	Amount 	% to Sale s 	Amount 	% to Sales 	Amount 	% to Sales
Sales to customers 	$1 3,873 	1 00.0 	$1 5,202 	1 00.0 	$1 5,563 	1 00.0 	$1 5,763 	1 00.0 	$60,401 	1 00.0
Cost of products sold (COGS) 	4,020 	29.0 	3,978 	26.2 	3,672 	23.6 	3,976 	25.2 	1 5,646 	25.9
Selling, marketing and administrative expenses (SM&A) 	2,261 	1 6.3 	2,789 	1 8.3 	2,869 	1 8.5 	3,456 	21 .9 	1 1 ,375 	1 8.8
Research and development expense (R&D)* 	2,548 	1 8.4 	2,869 	1 8.9 	2,944 	1 8.9 	3,466 	22.0 	1 1 ,827 	1 9.6
Other segment items 	1 	(1 66) 	(1 .2) 	1 4 	0.1 	(368) 	(2.4) 	(1 93) 	(1 .2) 	(71 3) 	(1 .2)
Adjusted segment income before tax 	2 	$5,21 0 	37.5 	$5,552 	36.5 	$6,446 	41 .4 	$5,058 	32.1 	$22,266 	36.9
Amount 	% to Sales 	Amount 	% to Sales 	Amount 	% to Sale s 	Amount 	% to Sales 	Amount 	% to Sales
Sales to customers 	$1 3,873 	1 00.0 	$1 5,202 	1 00.0 	$1 5,563 	1 00.0 	$1 5,763 	1 00.0 	$60,401 	1 00.0
Cost of products sold (COGS) 	3,371 	24.3 	3,1 80 	20.9 	3,093 	1 9.9 	3,261 	20.7 	1 2,905 	21 .4
Selling, marketing and administrative expenses (SM&A) 	2,261 	1 6.3 	2,789 	1 8.3 	2,869 	1 8.4 	3,456 	21 .9 	1 1 ,375 	1 8.8
Research and development expense (R&D)* 	2,548 	1 8.4 	2,869 	1 8.9 	2,944 	1 8.9 	3,466 	22.0 	1 1 ,827 	1 9.6
Other segment items 	1 	(204) 	(1 .5) 	(1 29) 	(0.8) 	(238) 	(1 .5) 	(1 35) 	(0.9) 	(706) 	(1 .2)
Adjusted segment income before tax 	2 	$5,897 	42.5 	$6,493 	42.7 	$6,895 	44.3 	$5,71 5 	36.3 	$25,000 	41 .4
As reported
Q1 	Q2 	Q3 	Q4 	YTD
Adjusted
Q1 	Q2 	Q3 	Q4 	YTD

-- 5 of 6 --

1 	Other segment items for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development
2 	Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the 	company's website
2025
(Unaudited; Dollar in millions)
Earnings before provision for taxes on income by segment
2
MedTech
Amount 	% to Sale s 	Amount 	% to Sales 	Amount 	% to Sales 	Amount 	% to Sales 	Amount 	% to Sales
Sales to customers 	$8,020 	1 00.0 	$8,541 	1 00.0 	$8,430 	1 00.0 	$8,801 	1 00.0 	$33,792 	1 00.0
Cost of products sold (COGS) 	3,326 	41 .5 	3,638 	42.6 	3,61 2 	42.9 	3,973 	45.1 	1 4,549 	43.1
Selling, marketing and administrative expenses (SM&A) 	2,656 	33.1 	2,862 	33.5 	2,801 	33.2 	3,035 	34.5 	1 1 ,354 	33.6
Research and development expense (R&D)* 	677 	8.4 	647 	7.6 	728 	8.6 	786 	8.9 	2,838 	8.4
Other segment items 	1 	(60) 	(0.7) 	1 90 	2.2 	2 	- 	806 	9.2 	938 	2.8
Adjusted segment income before tax 	2 	$1 ,421 	1 7.7 	$1 ,204 	1 4.1 	$1 ,287 	1 5.3 	$201 	2.3 	$4,1 1 3 	1 2.1
Amount 	% to Sale s 	Amount 	% to Sales 	Amount 	% to Sales 	Amount 	% to Sales 	Amount 	% to Sales
Sales to customers 	$8,020 	1 00.0 	$8,541 	1 00.0 	$8,430 	1 00.0 	$8,801 	1 00.0 	$33,792 	1 00.0
Cost of products sold (COGS) 	2,795 	34.8 	3,1 42 	36.8 	3,1 1 9 	37.0 	3,435 	39.0 	1 2,491 	37.0
Selling, marketing and administrative expenses (SM&A) 	2,656 	33.1 	2,862 	33.5 	2,801 	33.2 	3,035 	34.5 	1 1 ,354 	33.6
Research and development expense (R&D)* 	671 	8.4 	690 	8.1 	728 	8.6 	786 	8.9 	2,875 	8.5
Other segment items 	1 	(1 82) 	(2.2) 	(53) 	(0.6) 	1 5 	0.2 	1 0 	0.2 	(21 0) 	(0.6)
Adjusted segment income before tax 	2 	$2,080 	25.9 	$1 ,900 	22.2 	$1 ,767 	21 .0 	$1 ,535 	1 7.4 	$7,282 	21 .5
As reported
Q1 	YTD
Adjusted
Q1 	YTD
Q2
Q2
Q3
Q3
Q4
Q4

-- 6 of 6 --